Associate Director Community Outreach- 🫁Thoracic Oncology, University of Miami @SylvesterCancer , 🇵🇷Boricua, Co-founder @KidsHelpingKidsSucceed
Miami, FL
Joined June 2012
- Tweets14.7K
- Following3K
- Followers8.5K
- Likes19.2K
🚨#ESMO26 and last but not least Top Lung Abstract goes to the new Diva 💃 of #KRASG12C #lungcancer!
#KRASCENDO1: Phase III #Divarasib vs sotorasib/adagrasib after prior chemotherapy for #KRASG12C NSCLC
📈 PFS: 9.8 vs 5.7 mo (HR 0.58)
🔥 OS: ~18 vs 12 mo (HR 0.56)
🎯 ORR: 58.4% vs 32.3%
⚠️ Grade 3–4 TRAEs: 24.6% vs 34.5%
🏆This is clearly practice changing with a much better tolerated drug and fewer side effects ( although still GI toxicity) compared to current standard for this high-risk population.
🤔Still some questions about exclusion of untreated brain mets and low number of adagrasib treated pts in control arm
#lcsm @KRASKickers
🎉Congratulations to the investigators and grateful for the patients @SylvesterCancer who participated on this landmark trial for #KRASG12C #lungcancer @KRASKickers
nejm.org/doi/full/10.1056/NE…
#ESMO26 🇪🇸 Top Lung Abstracts 🫁
#SAFFRON Phase 3 study of #savolitinib + osimertinib vs. platinum–pemetrexed for MET- driven resistance post osimertinib (N=338)
🎯 MET IHC 3+/ Amp (FISH)>10
🎯 PFS: 7.6 vs 5.4 mo (HR 0.55)
🎯 OS: 17.8 vs 12.9 mo (HR 0.68)
🎯 ORR: 51% vs 27%
⚠️ AEs: Edema & GI toxicity
👉🏽 Clinical Challenge - Although MET resistance post osi can occur 20-30%, it is hard to test for this prospectively in clinic- requires repeat biopsy🔪
#LCSM #LungCancer @EGFRResisters
🚨 #ESMO26 | Top Lung Abstracts🫁
PERSEE: Phase 3 🇫🇷 study of pembrolizumab alone vs chemo+pembro for PD-L1-high
🔥 PFS: 16.1 vs 6.9 mo (HR 0.56)
🎯 ORR: 77.5% vs 50.3%
⚠️ Early progression: 5.8% vs 26.5%
📊 OS: 50.2 vs 29.9 mo (HR 0.77; NS)
👉🏽 Maybe more is better for select patients
👉🏽Benefit persisted even with PD-L1 ≥90%—but grade ≥3 TRAEs increased (53.8% vs 19.3%).
More disease control but more toxicity. #lcsm #immunotherapy
🤖 Made with AI
🚨 #ESMO26 | Top Lung Abstracts 🫁
OptiTROP-Lung04 (Phase III- China only trial)
Significant mOS 8.5 mo advantage for sac-TMT, a TROP2 ADC, after EGFR-TKI progression in EGFR-mutant NSCLC🫁 vs chemo!
📊 Median OS: 25.9 vs 17.4 months
🔥 HR 0.69 — 31% lower risk of death
⚠️ AEs- cytopenias, stomatitis, opthal, ILD
👉🏽Competes w Dato-DXd already approved in this EGFR+ population based on Tropion-Lung05, Lung01
👉🏽Global validation and treatment-sequencing questions remain.
@EGFRResisters
#LCSM #LungCancer #ESMO26
🇪🇸 #ESMO26 | Top Lung Abstracts 🫁
🚨 OPTITROP-Lung06: Phase III trial in PD-L1–negative, driver-negative nonsquamous NSCLC:
🔥 Median PFS: 15.0 vs 5.7 months
📉 HR 0.49 — 51% reduction in risk of progression/death
🎯 DOR: 13.6 vs 6.8 months
📊 12-mo OS: 77.6% vs 66.4% (immature data)
▶️ I wouldn’t call this a “chemo-free” regimen because the toxicity of an ADC is similar to chemo—> but this many be a potential option for this hard to treat PDL1 neg population.
▶️Could this change the 1L landscape? 👀maybe? but I would hope for a bigger survival advantage….data immature …
#LungCancer #LCSM #ADC
Dr. Estela Rodriguez retweeted
🔥NeoCOAST-2: ctDNA clearance & outcomes in resectable NSCLC
🆙 @Nature
☑Phase 2 platform; Arm 4 (Dato-DXd) highest ctDNA clearance (72.5%) & 24-mo EFS 77.9%
🎯ctDNA clearance → HR 0.22 for EFS (p<0.001)
🎯ctDNA clearance + pCR → EFS HR 0.10 (p=0.002)
🎙Dr. Lara McGrath @FordePatrick @MARIANOPROVENCI @DoctorJSpicer Dr. Tina Cascone
#LCSM @OncoAlert @Larvol
doi.org/10.1038/s41586-026-1…
🇪🇸 #ESMO26 Top Lung Abstracts | SARON 🫁
☢️In synchronous oligometastatic, driver-negative #NSCLC, adding consolidative RT to systemic therapy improved PFS (13.9 vs 8.9 months; HR 0.64) and local control.
❗But no OS benefit (HR 0.99; p=0.95).
Better disease control doesn’t always translate into longer survival! 🔬
#LungCancer #LCSM
🤖 Made with AI
#DeLLPhi305 Low US enrollment in this pivotal #SCLC trial is NOT surprising. Regulatory hurdles, costs & complexity push sponsors to conduct trials faster ex-US—even for drugs destined to be used at greater rates by US patients.
Why it matters:
▶️ Less evidence on implementation & AEs in diverse populations
▶️ Fewer opportunities for US investigators to shape drug development early
We need faster, more inclusive trials! 🔬#clinicaltrials #ESMO26 @SclcSMASHERS @GlopesMd
How is it possible that, with all these hospitals in the study actively recruiting, they contributed ONLY slightly more than ±10% of the patients for the study #DeLLphi-305? I can´t understand it #SCLC #Tarlatamab #ESMO26
